Mode
Text Size
Log in / Sign up

Renal perfusion pressure trajectories associate with outcomes in acute decompensated heart failure patients receiving PAC-guided therapy.

Renal perfusion pressure trajectories associate with outcomes in acute decompensated heart failure p…
Photo by César Badilla Miranda / Unsplash
Key Takeaway
Note that RPP trajectories associate with renal function and survival outcomes in PAC-guided heart failure therapy.

This randomized trial included 143 patients with acute decompensated heart failure who were randomized to PAC-guided therapy. The primary investigation focused on renal perfusion pressure (RPP) trajectories during hemodynamically guided therapy and their relationship to clinical outcomes.

Regarding renal safety, 17 patients (11.9%) experienced worsening renal function defined as a greater than 30% decrease in GFR. Analysis revealed a positive association between the percent change in GFR and the percent change in RPP, with an effect size of 0.248 (p = 0.02). This association remained significant after adjustment, showing an effect size of 0.22 (p = 0.033).

RPP trajectories demonstrated a significant association with overall survival (KM p < 0.001) and survival free of transplant, left ventricular assist device, or heart failure hospitalization (KM p = 0.002). Notably, favorable RPP trajectories were associated with improved outcomes in patients with elevated creatinine levels, specifically regarding overall survival (KM p < 0.001) and heart failure hospitalization (KM p < 0.001). No specific adverse events or discontinuations were reported in the provided data.

The study design limits causal inference regarding RPP trajectories. While the findings suggest a link between RPP changes and clinical status, the evidence is observational in its interpretation of RPP dynamics. Clinicians should consider these associations when evaluating hemodynamic monitoring strategies but must await further validation before altering standard care based solely on RPP metrics.

Study Details

Study typeRct
Sample sizen = 143
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Worsening renal function (WRF) during acute decompensated heart failure (ADHF) therapy portends worse outcomes. We hypothesized that renal perfusion pressure (RPP), systemic mean arterial pressure minus central venous pressure (CVP), is associated with and may elucidate mechanisms of WRF. We theorized that machine learning-based RPP trajectories could impact outcomes. METHODS: Patients in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization (PAC) Effectiveness (ESCAPE) Trial randomized to PAC-guided therapy were evaluated. M-estimation, logistic regression, and receiver operating characteristic analysis were performed. Trajectories were analyzed by selecting summary measures capturing the most variance in the trajectories using factor analysis and applying clustering with the k-means methods based on these summary measures. RESULTS: Among 143 patients (age 56.7 ± 13.8 years, 26.6 % female), 17 patients (11.9 %) had >30 % decrease in glomerular filtration rate (GFR) during therapy. Percent change in GFR (%∆GFR) was positively associated with percent change in RPP (%∆RPP) (M-estimation coefficient 0.248; p = 0.02). %∆GFR was associated with %∆RPP, controlling for body mass index and ischemic cardiomyopathy (M-estimation coefficients 0.22, -0.007, and - 0.109; p = 0.033). RPP trajectories were associated with overall survival [OS; Kaplan-Meier (KM) p < 0.001] and survival free of transplant, left ventricular assist device, and heart failure hospitalization (HFH, KM p = 0.002). Favorable RPP trajectory was associated with improved outcomes, even with elevated creatinine (OS: KM p < 0.001, HFH: KM p < 0.001). Mediation effect of CVP at discharge was 10.4 % and 10 % for baseline creatinine. CONCLUSIONS: RPP changes potentially explain a mechanism of WRF in patients undergoing PAC-guided therapy for ADHF. Trajectories of RPP predict survival and hospitalization outcomes and could improve nuanced risk stratification of cardiorenal syndromes in patients with ADHF.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.